The potential value of RAD50 missense variants is exemplified by a previous case report of synthetic lethality to DNA damage checkpoint inhibition in combination with DNA‐damaging chemotherapy in cancer cells harboring the RAD50*p.L1237F variant [13]. The gene discussed is RAD50; the disease is cancer.